Is this you?
Request access for Benchmark Research with your @benchmarkresearch.net work email. Intera will contact you to verify and set up your account — nothing auto-publishes.
Intera lens
ICP 5Lift (cardio sample) 0.24Recruit soph 0.14
Quality Scorecard (1–100)
Overall68Recruit67Ops75Sponsor64Ther65
Performance (observed)
Historical trials
191
Completed
166
Terminated/Withdrawn
9
Completion rate
95%
Active now
13
Phase 2
71
Phase 3
100
Realized enrollment
709,773
First study year
2004
Years active
21
Match confidence
high
Enrollment velocity (inf)
33,799
Therapeutic
Areas
Vaccines (specialty), General Medicine
Specialties
Vaccines, allergy, infectious disease, general medicine, COVID-19, obesity
Breadth (conditions)
139
Languages
English
States
Texas, California, Louisiana, Ecuador
Recruitment (web observed)
Trial Finder
Yes
SEO
Good (vaccine specialist, awards)
Capability notes
Leading vaccine site network; 1,000+ vaccine trials; 40,000+ trial participants; high-volume vaccine expertise; World Vaccine Congress award (5x)
Relationships
Sponsors
Pfizer; ModernaTX, Inc.; Novavax; Merck Sharp & Dohme LLC; Sanofi Pasteur, a Sanofi Company; MedImmune LLC
CROs
PPD Development, LP; Parexel; Syneos Health; Teva Branded Pharmaceutical Products R&D, Inc.
Owner / parent
Avacare Clinical Research Network (acquired into Avacare)
Funding
Acquired by Avacare Clinical Research Network
Acquisitions
Acquired by Avacare
Expansion
8 sites, acquired by Avacare 2023
Recent hiring
Unknown (part of Avacare)
Capacity & people
Investigators
—
Coordinators
—
CEO
Unknown (historical: Benchmark leadership; now Avacare)
VP Clinical Ops
Unknown
VP Site Ops
Scott Barrett (COO, historical)
VP Recruitment
Unknown
Emails
webcontact-bmr@avacare.com
Tech & DCT
eSource
Yes
Builds tech
Vendors (CRIO eSource)
DCT / decentralized
Y - 8 sites (TX, CA, LA, Ecuador)
Tech stack
CRIO eSource platform; data quality/patient safety tech
Recruiting visible
Y
Notes
Moderate Intera fit: Highly specialized vaccine network (not ideal for Intera's multi-therapeutic focus); 10 sites with proven 1,000+ vaccine trial execution and high recruitment quality. Recent acquisition into Avacare may limit independence. Excellent in niche but too specialized and small-scale for Intera's broad platform.
Recommendation features (sample indication)
Ind fit 0.28Liftability 0.24Overall68
FUTURE MOAT: absolute enrollment rates, funnel CPR, measured SSU, screen-fail reasons.